Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Return on Capital Employed (2018 - 2026)

Lexaria Bioscience's Return on Capital Employed history spans 9 years, with the latest figure at 1.56% for Q1 2026.

  • Quarterly results put Return on Capital Employed at 1.56% for Q1 2026, down 30.0% from a year ago — trailing twelve months through Feb 2026 was 1.56% (down 30.0% YoY), and the annual figure for FY2025 was 2.36%, down 118.0%.
  • Return on Capital Employed for Q1 2026 was 1.56% at Lexaria Bioscience, up from 2.94% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 450.72% in Q1 2024 to a low of 7.83% in Q2 2023.
  • The 5-year median for Return on Capital Employed is 1.69% (2024), against an average of 28.74%.
  • The sharpest move saw Return on Capital Employed skyrocketed 45517bps in 2024, then crashed -45199bps in 2025.
  • Year by year, Return on Capital Employed stood at 1.72% in 2022, then crashed by -139bps to 4.11% in 2023, then surged by 80bps to 0.81% in 2024, then crashed by -264bps to 2.94% in 2025, then skyrocketed by 47bps to 1.56% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 1.56%, 2.94%, and 3.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.